FLAG-IDA with venetoclax shows promise as frontline therapy for pediatric AML. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes and many proceeded to transplant. Common toxicities included cytopenias comparable to previous regimens.

Subjects:
Myeloid Neoplasia
This content is only available as a PDF.
Copyright © 2025 American Society of Hematology
2025

Article PDF first page preview

First page of FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML
You do not currently have access to this content.
Sign in via your Institution